Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC
SHANGHAI and SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced that it has submitted four investigational new drug (IND) applications...
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia showing that treatment with oral opaganib (ABC294640) vs. the...
NCCN Meeting on Blood Cancers Empowers Interprofessional Care Teams
The NCCN 2021 Virtual Congress: Hematologic Malignancies ( #NCCNhem21 ) will provide the latest evidence and expert consensus on emerging practices and issues in blood cancer treatment, online October 14-16, 2021. PLYMOUTH MEETING, Pa., Oct. 4, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) will conduct a three-day, live virtual congress October 14-16, 2021...
Yuanta Securities Co., Ltd. Awarded for ‘The Pioneer of the Securities Industry-Yuanta Human Capital Boosting Program’ under Investment In People Category
SINGAPORE, Oct. 4, 2021 /PRNewswire/ -- Enterprise Asia, the organiser of the tenth Asia Responsible Enterprise Awards (AREA) 2021, is pleased to recognise 69 outstanding award recipients who exemplified determination and perseverance despite the trying times. Yuanta Securities Co., Ltd. awarded in the Investment In People Category at Asia Responsible Enterprise Awards 2021 The AREA is...
Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US
SUZHOU, China, Oct. 4, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that on October 1 its phase III clinical trial of proxalutamide for the treatment of hospitalized COVID-19 patients has enrolled and dosed its first patient in the United States. Proxalutamide is the...
Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award
LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Shumpei Ishikawa and Translational Research – Dr. Hiromichi Ebi. The winners were honored with trophies and a monetary prize during the hybrid...
TOGL Technology Sdn Bhd Awarded at the Asia Responsible Enterprise Awards 2021 for ‘Toga Resonance Technology (T-RT)’ under Health Promotion Category
SINGAPORE, Oct. 4, 2021 /PRNewswire/ -- Enterprise Asia, the organiser of the tenth Asia Responsible Enterprise Awards (AREA) 2021, is pleased to recognise 69 outstanding award recipients and who exemplified determination and perseverance despite the trying times. TOGL Technology Sdn Bhd awarded for Health Promotion Category at the Asia Responsible Enterprise Awards 2021 The AREA is...
New Research in Kosovo Highlights Connection Between Children’s Poor Vision and Learning and Development
Study underscores link between uncorrected poor vision and children's potential DALLAS, Oct. 4, 2021 /PRNewswire/ -- A new study, a collaboration of the Vision Impact Institute, EdGuard Institute, and ESSILOR's Vision for Life™ social impact fund, offers new insight into the correlation between uncorrected poor vision and children's functional, learning, and behavioral capacities....
Chiranya Prachaseri recognized as Asia’s Most Inspiring Executives
BANGKOK, Oct. 4, 2021 /PRNewswire/ -- "As recognized by the ACES Awards 2021 for the Asia's Most Inspiring Executives award, it is such a great honor not only me but also everyone in Cryoviva for being a team player and builder together", said Chiranya Prachaseri, Chief Executive Officer of Cryoviva (Thailand) Ltd., and Director of Cryoviva Singapore Pte....
Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, presented at IDWeek 2021 interim results from Phase 3 of the ACTIV-2 trial, which showed that BRII-196/BRII-198 ("combination BRII-196/BRII-198"), the Company's neutralizing monoclonal antibody (mAb)...
